Evolving Therapeutic Approaches and Shifting Paradigms in the Treatment of Multiple Myeloma

Evolving Therapeutic Approaches and Shifting Paradigms in the Treatment of Multiple Myeloma

Program Summary

Over the last decade, advances made in the understanding and therapeutic targeting of biologic and genetic mechanisms involved in the pathogenesis of multiple myeloma (MM) have steadily enhanced clinical outcomes. While multiple myeloma (MM) remains incurable, survival benefits afforded by new therapeutic and management strategies are leading to a significant present day paradigm shift of consideration of MM as a chronic disease to be managed, rather than an inevitably fatal cancer.

This activity brings leading myeloma experts together to discuss some of the most important issues in myeloma today, including current and future practice for patients with smoldering myeloma, the development of novel targeted therapies; evolving clinical paradigms on timing of HDT-ASCT and continuous /maintenance therapy; the evolution of treatment strategies to overcome acquired resistance to therapy including new combination therapies and new classes of therapeutics never before used in multiple myeloma

Target Audience

This educational activity is designed to meet the educational needs of hematologists, medical oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians’ assistants, etc.) involved and/or interested in the therapeutic management of patients with MM.

Educational Objectives

After completing this program, participants should be able to:

1. Describe current treatment strategies and supporting rationales for the individualized management of transplant-eligible, as well as elderly multiple myeloma patients throughout the lifecycle of the disease

2. Assess the shifting treatment paradigms of multiple myeloma including emerging regimens used in smoldering myeloma, primary therapy, consolidation therapy, maintenance therapy, and relapsed/ refractory disease

3. Evaluate finalized and ongoing clinical trial data utilizing standard of care and/or investigational therapies that have the potential to enhance clinical outcomes in newly diagnosed, elapsed/refractory, and non-transplant eligible

4. Summarize emerging new classes of therapeutics and potential combinations, primarily in the relapsed/ refractory setting
Rush University Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Rush University Medical Center designates this Live Activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Rush University designates this live activity for one (1) Continuing Education credit(s).

This activity is being presented without bias and with commercial support.


acpe logo newEducational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1 hour (0.1 CEUs) of continuing pharmacy education credit.  Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.  Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. UAN  # 0761-9999-16-107-L01-P
Ange Paner, MD (Chair)
Rush University Medical Center

Chicago, IL

Jatin J. Shah, MD (Chair)
The University of Texas MD Anderson Cancer Center

Houston, TX

Rafael Fonseca, MD
Mayo Clinic
Scottsdale, Arizona

Ola Landgren, MD
Memorial Sloan Kettering Cancer Center
New York, New York

Philip McCarthy, MD
Roswell Park Cancer Institute
Buffalo, NY

Johnathan L. Kaufman, MD
Winship Cancer Institute of Emory University
Atlanta, GA 


Please fill in this form to request a hospital meeting.

Your Contact Information

Meeting Specifics

This activity is supported by independent educational grants from AbbVie, Celgene Corporation, Pharmacyclics, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Millennium: The Takeda Oncology Company and Spectrum Pharmaceuticals Inc.

Categories: Hospital Events

Social Buttons